Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biochymal in Ischemic Limb Disease
NCT02336646Phase 1Completed
- Sponsor
- Taiwan Bio Therapeutics
- Start
- May 2015
- Primary completion
- Apr 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of Biochymal in critical limb ischemia (CLI) (3 arms), sponsored by Taiwan Bio Therapeutics. Primary endpoint: Adverse events at 6 months. Started May 2015; status: completed.
02
Drugs
Biochymal
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02336646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336646.